

Marc E Buyse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4578164/publications.pdf>

Version: 2024-02-01

133
papers

16,155
citations

36691

53
h-index

18400

124
g-index

139
all docs

139
docs citations

139
times ranked

16543
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 229-237.	0.8	2,718
2	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192.	3.0	1,128
3	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. <i>Clinical Cancer Research</i> , 2007, 13, 3207-3214.	3.2	839
4	OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 394-400.	0.8	750
5	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1729.	3.8	711
6	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607
7	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	0.8	539
8	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. <i>Lancet, The</i> , 2000, 356, 373-378.	6.3	395
9	Criteria for the Validation of Surrogate Endpoints in Randomized Experiments. <i>Biometrics</i> , 1998, 54, 1014.	0.8	364
10	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
11	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3097-3104.	0.8	327
12	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5218-5224.	0.8	321
13	Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1987-1992.	0.8	314
14	Adjuvant Therapy of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1988, 259, 3571.	3.8	296
15	Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. <i>Journal of the National Cancer Institute</i> , 2007, 99, 998-1003.	3.0	291
16	Biomarkers and surrogate end points—the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 309-317.	12.5	283
17	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551.	4.3	222
18	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	0.8	220

#	ARTICLE	IF	CITATIONS
19	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1980-1986.	0.8	189
20	Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 3764-3775.	0.8	185
21	Validation of surrogate end points in multiple randomized clinical trials with failure time end points. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 405-422.	0.5	163
22	Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. <i>Pharmaceutical Statistics</i> , 2006, 5, 173-186.	0.7	150
23	Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1958-1962.	0.8	148
24	Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. <i>Statistics in Medicine</i> , 2010, 29, 3245-3257.	0.8	147
25	The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. , 1999, 18, 3435-3451.		145
26	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology</i> , The, 2009, 10, 341-350.	5.1	138
27	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
28	Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 484-492.	0.8	133
29	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
30	Ensuring trial validity by data quality assurance and diversification of monitoring methods. <i>Clinical Trials</i> , 2008, 5, 49-55.	0.7	129
31	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 171-182.	1.5	124
32	Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. <i>BMJ</i> , The, 2013, 346, f457-f457.	3.0	119
33	ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME. , 1996, 15, 2797-2812.		110
34	Statistical challenges in the evaluation of surrogate endpoints in randomized trials. <i>Contemporary Clinical Trials</i> , 2002, 23, 607-625.	2.0	108
35	Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 886-893.	5.1	104
36	Data Sharing, Year 1 " Access to Data from Industry-Sponsored Clinical Trials. <i>New England Journal of Medicine</i> , 2014, 371, 2052-2054.	13.9	101

#	ARTICLE	IF	CITATIONS
37	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.1	101
38	Data fraud in clinical trials. <i>Clinical Investigation</i> , 2015, 5, 161-173.	0.0	94
39	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. <i>Biometrical Journal</i> , 2016, 58, 104-132.	0.6	93
40	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage IIâ€“III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	3.0	89
41	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
42	Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step. <i>Journal of Clinical Oncology</i> , 2004, 22, 3839-3841.	0.8	85
43	A statistical approach to central monitoring of data quality in clinical trials. <i>Clinical Trials</i> , 2012, 9, 705-713.	0.7	83
44	Should Dukes' B patients receive adjuvant therapy? A statistical perspective. <i>Seminars in Oncology</i> , 2001, 28, 20-24.	0.8	82
45	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	3.0	78
46	Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. <i>Journal of Rheumatology</i> , 2007, 34, 607-15.	1.0	78
47	Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. <i>Statistics in Medicine</i> , 2001, 20, 3023-3038.	0.8	77
48	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 7007-7013.	0.6	73
49	Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2045-2047.	0.8	69
50	The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2004, 167, 103-124.	0.6	69
51	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 312-324.	0.2	69
52	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. <i>Journal of Clinical Oncology</i> , 2007, 25, 3572-3575.	0.8	66
53	Individual- and trial-level surrogacy in colorectal cancer. <i>Statistical Methods in Medical Research</i> , 2008, 17, 467-475.	0.7	65
54	Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1750-1754.	0.8	63

#	ARTICLE	IF	CITATIONS
55	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60
56	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , 2019, 20, 361-370.	5.1	59
57	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , 2020, 21, e252-e264.	5.1	56
58	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv261.	3.0	53
59	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz002.	1.4	52
60	A unifying approach for surrogate marker validation based on Prentice's criteria. <i>Statistics in Medicine</i> , 2006, 25, 205-221.	0.8	51
61	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy. <i>An Aide et Recherche en Cancérologie Digestive Group Study. Journal of Clinical Oncology</i> , 2011, 29, 4199-4204.	0.8	51
62	Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints. <i>Biometrics</i> , 2004, 60, 724-728.	0.8	49
63	Data Sharing "Is the Juice Worth the Squeeze?". <i>New England Journal of Medicine</i> , 2016, 375, 1608-1609.	13.9	49
64	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 833-842.	2.4	48
65	The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. <i>JAMA Oncology</i> , 2016, 2, 901.	3.4	47
66	Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes. <i>Biometrical Journal</i> , 2002, 44, 921-935.	0.6	44
67	Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. <i>BMJ Open</i> , 2013, 3, e001802.	0.8	43
68	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1230-1239.	0.7	43
69	On the Relationship between the Causal-Inference and Meta-Analytic Paradigms for the Validation of Surrogate Endpoints. <i>Biometrics</i> , 2015, 71, 15-24.	0.8	41
70	Simplified hierarchical linear models for the evaluation of surrogate endpoints. <i>Journal of Statistical Computation and Simulation</i> , 2003, 73, 643-658.	0.7	40
71	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	3.0	40
72	Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 421-425.	1.0	38

#	ARTICLE	IF	CITATIONS
73	Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. <i>Haematologica</i> , 2011, 96, 1106-1112.	1.7	33
74	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 713-719.	4.9	33
75	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	21.5	32
76	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008, 14, 54-64.	0.4	30
77	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	1.9	29
78	Reformulating the hazard ratio to enhance communication with clinical investigators. <i>Clinical Trials</i> , 2008, 5, 641-642.	0.7	26
79	Validation of a longitudinally measured surrogate marker for a time-to-event endpoint. <i>Journal of Applied Statistics</i> , 2003, 30, 235-247.	0.6	24
80	Open science: The open clinical trials data journey. <i>Clinical Trials</i> , 2019, 16, 539-546.	0.7	24
81	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011, 55, 2748-2757.	0.7	23
82	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 82953-82960.	0.8	22
83	Issues of efficiency in combining proportions of deaths from several clinical trials. <i>Statistics in Medicine</i> , 1987, 6, 565-576.	0.8	21
84	Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments. <i>Current Opinion in Oncology</i> , 2008, 20, 466-471.	1.1	20
85	Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. <i>Gastric Cancer</i> , 2016, 19, 24-30.	2.7	20
86	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.	1.0	19
87	The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. <i>Journal of Statistical Planning and Inference</i> , 2008, 138, 432-449.	0.4	17
88	Commentary on Hey and Kimmelman. <i>Clinical Trials</i> , 2015, 12, 119-121.	0.7	17
89	Applied Surrogate Endpoint Evaluation Methods with SAS and R. , 0, , .		17
90	Towards validation of statistically reliable biomarkers. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 89-95.	2.2	16

#	ARTICLE	IF	CITATIONS
91	Omics-based clinical trial designs. <i>Current Opinion in Oncology</i> , 2013, 25, 289-295.	1.1	16
92	Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed!. <i>Journal of Clinical Oncology</i> , 2007, 25, 5673-5674.	0.8	15
93	The impact of data errors on the outcome of randomized clinical trials. <i>Clinical Trials</i> , 2017, 14, 499-506.	0.7	15
94	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. <i>Biometrics</i> , 2012, 68, 248-257.	0.8	14
95	Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 1-11.	0.6	14
96	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. <i>Contemporary Clinical Trials</i> , 2020, 99, 106189.	0.8	14
97	Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019, 16, 512-522.	0.7	13
98	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1186-1191.	3.0	13
99	The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 275-280.	0.5	13
100	Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1682-1687.	0.8	12
101	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019, 28, 170-183.	0.7	12
102	Unbiasedness and efficiency of non-parametric and UMVUE estimators of the probabilistic index and related statistics. <i>Statistical Methods in Medical Research</i> , 2021, 30, 747-768.	0.7	12
103	Meta-analysis of randomized clinical trials in the era of individual patient data sharing. <i>International Journal of Clinical Oncology</i> , 2018, 23, 403-409.	1.0	11
104	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1619-1627.	0.5	11
105	Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2009, 14, 95-101.	1.0	10
106	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
107	The ARCAD Clinical Trials Program: An Update and Invitation. <i>Oncologist</i> , 2012, 17, 188-191.	1.9	9
108	Central statistical monitoring of investigator-led clinical trials in oncology. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1207-1214.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 125-131.	2.0	8
110	The search for surrogate endpoints for immunotherapy trials. <i>Annals of Translational Medicine</i> , 2018, 6, 231-231.	0.7	8
111	Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. <i>Trials</i> , 2011, 12, 86.	0.7	7
112	Evaluation of Continuous Tumor-Sizeâ€‘Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
113	The Net Benefit of a treatment should take the correlation between benefits and harms into account. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 148-158.	2.4	6
114	Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints. <i>Current Opinion in Oncology</i> , 2020, 32, 384-390.	1.1	5
115	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. <i>Statistics in Medicine</i> , 2021, 40, 553-565.	0.8	5
116	Recent meta-analyses in colorectal cancer. <i>Current Opinion in Oncology</i> , 2000, 12, 362-367.	1.1	4
117	Neoadjuvant as Future for Drug Development in Breast Cancerâ€‘Letter. <i>Clinical Cancer Research</i> , 2016, 22, 268-268.	3.2	4
118	A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons. <i>Biometrical Journal</i> , 2021, 63, 272-288.	0.6	4
119	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
120	Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 417-425.	1.1	3
121	Correcting the bias of the net benefit estimator due to rightâ€‘censored observations. <i>Biometrical Journal</i> , 2021, 63, 893-906.	0.6	3
122	Phase III design: principles. <i>Chinese Clinical Oncology</i> , 2016, 5, 10.	0.4	3
123	Fraud in clinical trials: complex problem, simple solutions?. <i>International Journal of Clinical Oncology</i> , 2016, 21, 13-14.	1.0	2
124	Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3442.	1.7	2
125	Generalized Pairwise Comparisons for Prioritized Outcomes. , 2021, , 1-25.		2
126	Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. <i>Statistics in Medicine</i> , 2001, 20, 3023-3038.	0.8	2

#	ARTICLE	IF	CITATIONS
127	Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.. Journal of Clinical Oncology, 2013, 31, 3533-3533.	0.8	2
128	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. Journal of Clinical Oncology, 2014, 32, 3538-3538.	0.8	2
129	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. Journal of Clinical Oncology, 2014, 32, 3578-3578.	0.8	2
130	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
131	Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses. , 0, , 183-190.		1
132	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. Journal of Clinical Oncology, 2015, 33, 666-666.	0.8	1
133	Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. Contemporary Clinical Trials, 2021, 105, 106400.	0.8	0